.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,057,292

« Back to Dashboard
Patent 6,057,292 protects SOMAVERT and is included in one NDA.

This patent has fifty patent family members in fifteen countries.

Summary for Patent: 6,057,292

Title: Method for inhibiting growth hormone action
Abstract:Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
Inventor(s): Cunningham; Brian C. (San Bruno, CA), Lowman; Henry B. (Hercules, CA), Wells; James A. (Burlingame, CA), Clark; Ross G. (Pacifica, CA), Olson; Kenneth (Burlingame, CA), Fuh; Germaine G. (Pacifica, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:09/028,587
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 27th percentile
Forward Citations: 6th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-001Mar 25, 2003RXYes6,057,292► subscribe ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-002Mar 25, 2003RXYes6,057,292► subscribe ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
Pharmacia And Upjohn
SOMAVERT
pegvisomant
INJECTABLE;SUBCUTANEOUS021106-003Mar 25, 2003RXYes6,057,292► subscribe ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,057,292

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1► subscribe
5,955,346 Variants of human prolactin and human placeatal lactogen► subscribe
5,834,598 Human growth hormone variants► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,057,292

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria164395► subscribe
Austria189526► subscribe
Austria301196► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc